THE PATHWAY TO PRESCRIPTION IS COMPLICATED

...Especially for Sepsis Patients

39-year-old woman with history of ovarian cysts and pyelonephritis exhibiting symptoms of fever and urinary discomfort.

Patient goes to Emergency Room.

Patient is admitted and suspected to be septic based on initial labs. Sepsis bundle initiated.

Patient is started on broad spectrum antibiotic Ceftriaxone, but symptoms continue to worsen.

Patient symptoms improve and she is discharged on oral antibiotics.

Beckman Coulter MicroScan platform results confirm that an ESBL-producing organism is causing the infection. The isolate was identified to be susceptible to meropenem and trimethoprim-sulfamethoxazole but intermediate to ceftriaxone.

Beckman Coulter MicroScan platform results confirm that an ESBL-producing organism is causing the infection. The isolate was identified to be susceptible to meropenem and trimethoprim-sulfamethoxazole but intermediate to ceftriaxone.

With increasing frequency, UTIs caused by ESBL-producing Enterobacterales are seen in outpatients with no previous healthcare exposures. 1

Beckman Coulter’s MicroScan panels feature drugs recommended by IDSA* and the ECDC** to treat pyelonephritis and complicated urinary tract infections caused by ESBLs which include: ertapenem, meropenem, imipenem-cilastatin, ciprofloxacin, levofloxacin and trimethoprim-sulfamethoxazole. 2

To learn more about how beckman coulter’s solutions can impact sepsis patient management in your facility, click the link below:

LEARN MORE

2 World Health Statistics 2022, pg. 33
*IDSA- Infectious Disease Society of America
**ECDC- European Centre for Disease Prevention and Control
© 2022 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter Inc. in the United States and other countries. For Beckman Coulter’s worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact